Demographic parameters of patients with normal liver function (Group 1) and patients with mild to moderate hepatic dysfunction (Group 2)
| Values are given as arithmetic means (± SD) and range. | ||||
|---|---|---|---|---|
| Group 1 Patients with normal liver function (n = 17)a | Group 2 Patients with liver dysfunction (n = 16)b | |||
| Demographic data | ||||
| Age (years) | 59 ± 13.9 (34–84) | 62 ± 10.9 (44–84) | ||
| Weight (kg) | 66.9 ± 16.8 (45–94) | 67.4 ± 10.4 (44–84) | ||
| Body surface area (m2) | 1.76 ± 0.23 (1.49–2.22) | 1.79 ± 0.15 (1.41–2.00) | ||
| Sex (males/females) | 10/7 | 12/4 | ||
| Race (Caucasian) | 17 | 16 | ||
| Karnofsky status (%) | 85.3 ± 11.2 (60–100) | 76.7 ± 11.1 (60–90) | ||
| Liver functionc | ||||
| Hepatic dysfunction score (points) | 0–2 | 5–9 | ||
| Total BILI (μmol/liter) | 12 ± 5.9 (4–27) | 112 ± 153 (16–485) | ||
| AST (IU/liter) | 39.5 ± 41.9 (6–171) | 107 ± 34.1 (46–174) | ||
| ALT (IU/liter) | 27.1 ± 15.4 (7–58) | 112 ± 94.0 (19–341) | ||
| AP (IU/liter) | 231 ± 150 (76–511) | 1816 ± 1096 (370–3233) | ||
a Evaluated for pharmacokinetics n = 14.
b Evaluated for pharmacokinetics n = 13.
c Patients evaluated for pharmacokinetics.